Cooper Companies (NASDAQ:COO) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

Cooper Companies (NASDAQ:COO – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other equities analysts have also weighed in on COO. Weiss Ratings restated a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. Mizuho set a $75.00 target price on shares of Cooper Companies and gave the stock an “outperform” rating in a report on Thursday. Piper Sandler lowered shares of Cooper Companies from an “overweight” rating to a “neutral” rating and cut their target price for the company from $86.00 to $59.00 in a research note on Thursday. William Blair cut shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a report on Thursday. Finally, Citigroup restated a “neutral” rating and issued a $60.00 price target (down from $80.00) on shares of Cooper Companies in a research report on Thursday. Five analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Cooper Companies presently has a consensus rating of “Hold” and a consensus target price of $71.47.

Check Out Our Latest Research Report on COO

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $53.91 on Friday. The business has a fifty day simple moving average of $71.62 and a 200-day simple moving average of $69.61. Cooper Companies has a fifty-two week low of $51.01 and a fifty-two week high of $89.83. The firm has a market cap of $10.25 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 2.19 and a beta of 0.82. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO – Get Free Report) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. During the same period in the previous year, the company earned $0.49 earnings per share. Cooper Companies’s revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts forecast that Cooper Companies will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its Board of Directors has authorized a share buyback program on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to buy up to 22.7% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s management believes its stock is undervalued.

Institutional Trading of Cooper Companies

Institutional investors and hedge funds have recently bought and sold shares of the stock. New York Life Investment Management LLC boosted its holdings in shares of Cooper Companies by 0.6% during the 4th quarter. New York Life Investment Management LLC now owns 27,344 shares of the medical device company’s stock worth $2,241,000 after buying an additional 158 shares during the period. Root Financial Partners LLC grew its stake in Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares during the last quarter. Essential Partners LLC raised its holdings in Cooper Companies by 23.4% in the 1st quarter. Essential Partners LLC now owns 874 shares of the medical device company’s stock worth $62,000 after acquiring an additional 166 shares during the period. Allworth Financial LP raised its holdings in Cooper Companies by 14.1% in the 4th quarter. Allworth Financial LP now owns 1,355 shares of the medical device company’s stock worth $111,000 after acquiring an additional 167 shares during the period. Finally, SJS Investment Consulting Inc. lifted its position in Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after acquiring an additional 187 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies News Roundup

Here are the key news stories impacting Cooper Companies this week:

  • Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
  • Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
  • Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
  • Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
  • Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
  • Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

About Cooper Companies

(Get Free Report)

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

Featured Stories